S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:ORMP

Oramed Pharmaceuticals Stock Forecast, Price & News

$20.21
+1.29 (+6.82%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.36
$20.50
50-Day Range
$18.21
$29.75
52-Week Range
$3.44
$31.54
Volume
649,527 shs
Average Volume
747,007 shs
Market Capitalization
$657.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.79
30 days | 90 days | 365 days | Advanced Chart
Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Oramed Pharmaceuticals logo

About Oramed Pharmaceuticals

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORMP
Employees
12
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.71 million
Book Value
$1.40 per share

Profitability

Net Income
$-11.51 million
Net Margins
-680.53%
Pretax Margin
-696.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
28,970,000
Market Cap
$657.11 million
Optionable
Optionable

Company Calendar

Last Earnings
7/13/2021
Today
11/28/2021
Next Earnings (Estimated)
11/30/2021
Fiscal Year End
8/31/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

414th out of 1,391 stocks

Pharmaceutical Preparations Industry

189th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

Is Oramed Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Oramed Pharmaceuticals stock.
View analyst ratings for Oramed Pharmaceuticals
or view top-rated stocks.

How has Oramed Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ORMP stock has increased by 510.6% and is now trading at $20.21.
View which stocks have been most impacted by COVID-19
.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 30th 2021.
View our earnings forecast for Oramed Pharmaceuticals
.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its earnings results on Tuesday, July, 13th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.03. The biotechnology company earned $0.68 million during the quarter, compared to analysts' expectations of $0.70 million. Oramed Pharmaceuticals had a negative trailing twelve-month return on equity of 40.91% and a negative net margin of 680.53%.
View Oramed Pharmaceuticals' earnings history
.

What price target have analysts set for ORMP?

4 equities research analysts have issued 1 year price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $30.00 to $40.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $35.00 in the next year. This suggests a possible upside of 73.2% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the following people:
  • Nadav Kidron, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Joshua Hexter, Chief Operating & Business Officer
  • David Silberman, Chief Financial Officer, Secretary & Treasurer
  • Miriam Kidron, Director & Chief Scientific Officer
  • Michael Rabinowitz, Chief Commercial Officer

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.41%), Invesco Ltd. (2.32%), Altium Capital Management LP (1.52%), Moors & Cabot Inc. (1.34%), Geode Capital Management LLC (0.76%) and Morgan Jess S & Co. Inc. (0.66%). Company insiders that own Oramed Pharmaceuticals stock include Kevin Rakin and Nadav Kidron.
View institutional ownership trends for Oramed Pharmaceuticals
.

Which major investors are selling Oramed Pharmaceuticals stock?

ORMP stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, California State Teachers Retirement System, Goldman Sachs Group Inc., Barclays PLC, New York State Common Retirement Fund, WINTON GROUP Ltd, and McIlrath & Eck LLC. Company insiders that have sold Oramed Pharmaceuticals company stock in the last year include Kevin Rakin, and Nadav Kidron.
View insider buying and selling activity for Oramed Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Oramed Pharmaceuticals stock?

ORMP stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Altium Capital Management LP, Moors & Cabot Inc., Morgan Jess S & Co. Inc., BlackRock Inc., Calamos Advisors LLC, Jetstream Capital LLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Oramed Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $20.21.

How much money does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals has a market capitalization of $657.11 million and generates $2.71 million in revenue each year. The biotechnology company earns $-11.51 million in net income (profit) each year or ($0.69) on an earnings per share basis.

How many employees does Oramed Pharmaceuticals have?

Oramed Pharmaceuticals employs 12 workers across the globe.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is www.oramed.com.

Where are Oramed Pharmaceuticals' headquarters?

Oramed Pharmaceuticals is headquartered at 1185 AVENUE SUITE 228, NEW YORK NY, 10036.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at (844) 967-2633, via email at [email protected], or via fax at 972-2566-0004.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.